Moreover, many in the field sustain that failure of the clinical trials against AD depended upon the fact that intervention occurred too late in the disease (i.e. after tau pathology has been triggered by Aβ) when it could no longer be stopped. The gene discussed is MAPT; the disease is Alzheimer disease.